(2S,13BS)-2-METHOXY-2,3,5,6,8,9,10,13-OCTAHYDRO-1H,12H-BENZO[I]PYRANO[3,4-G]INDOLIZIN-12-ONE HYDROBROMIDE
生物活性体内研究 用途与合成方法 MSDS (2S,13BS)-2-METHOXY-2,3,5,6,8,9,10,13-OCTAHYDRO-1H,12H-BENZO[I]PYRANO[3,4-G]INDOLIZIN-12-ONE HYDROBROMIDE价格(试剂级) 上下游产品信息
| 中文名称 | (2S,13BS)-2-METHOXY-2,3,5,6,8,9,10,13-OCTAHYDRO-1H,12H-BENZO[I]PYRANO[3,4-G]INDOLIZIN-12-ONE HYDROBROMIDE |
|---|---|
| 中文同义词 | 化合物 T11041;(2S,13BS)-2-METHOXY-2,3,5,6,8,9,10,13-OCTAHYDRO-1H,12H-BENZO[I]PYRANO[3,4-G]INDOLIZIN-12-ONE HYDROBROMIDE |
| 英文名称 | (2S,13BS)-2-METHOXY-2,3,5,6,8,9,10,13-OCTAHYDRO-1H,12H-BENZO[I]PYRANO[3,4-G]INDOLIZIN-12-ONE HYDROBROMIDE |
| 英文同义词 | (2S,13BS)-2-METHOXY-2,3,5,6,8,9,10,13-OCTAHYDRO-1H,12H-BENZO[I]PYRANO[3,4-G]INDOLIZIN-12-ONE HYDROBROMIDE;3BETA-1,6-DIDEHYDRO-14,17-DIHYDRO-3-METHOXY-16(15H)-OXAERYTHRINAN-15-ONE HYDROBROMIDE;DIHYDRO-B-ERYTHROIDINE HYDROBROMIDE;DIHYDRO-BETA-ERYTHROIDINE HYDROBROMIDE;DIHYDRO-B-ERYTHROIDINE HYDROBROMIDE COMP ETITIVE NICOTINIC;3β-1,6-Didehydro-14,17-dihydro-3-methoxy-16(15H)-oxaerythrinan-15-one hydrobromide;Dihydro-β-erythroidine hydrobromide;-erythroidine hydrobromide |
| CAS号 | 29734-68-7 |
| 分子式 | C16H21NO3.BrH |
| 分子量 | 356.25 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 29734-68-7.mol |
| 结构式 | ![(2S,13BS)-2-METHOXY-2,3,5,6,8,9,10,13-OCTAHYDRO-1H,12H-BENZO[I]PYRANO[3,4-G]INDOLIZIN-12-ONE HYDROBROMIDE 结构式](CAS/GIF/29734-68-7.gif) |
(2S,13BS)-2-METHOXY-2,3,5,6,8,9,10,13-OCTAHYDRO-1H,12H-BENZO[I]PYRANO[3,4-G]INDOLIZIN-12-ONE HYDROBROMIDE 性质
| 储存条件 | Desiccate at RT |
|---|---|
| 溶解度 | 乙醇：5mg/mL |
| 形态 | 固体 |
| 熔点 | 219-229 °C (decomp) |
| 颜色 | 白色 |
(2S,13BS)-2-METHOXY-2,3,5,6,8,9,10,13-OCTAHYDRO-1H,12H-BENZO[I]PYRANO[3,4-G]INDOLIZIN-12-ONE HYDROBROMIDE 用途与合成方法
Dihydro-β-erythroidine (DHβE) hydrobromide 是一种有效竞争性的，具有口服活性的神经 nAChRs 拮抗剂。Dihydro-β-erythroidine hydrobromide 对 α4β4 和 α4β2 有选择性，IC50 分别为 0.19 和 0.37 μM。具有抗抑郁类活性。
Dihydro-Beta-Erythroidine hydrobromide (DHβE hydrobromide; 10 nmol/0.5 μL) is infused into the respective areas prior to a systemic nicotine injection (0.2 mg/kg; SC). DHβE infused into the ventral tegmental area (VTA), nucleus accumbens (NAcc), or infralimbic (IL) cortex, but not prelimbic (PrL) cortex, attenuated nicotine-enhanced responding for a conditioned reinforcer (CRf).
The co-administration of Dihydro-Beta-Erythroidine hydrobromide (5.0 mg/kg; s.c) with nicotine (0.2 and 0.4 mg/kg; s.c.) prevents the development of conditioned taste aversions (CTAs).
| Animal Model: | Male hooded Lister rats |
| Dosage: | 0.5, 1.6 and 5.0 mg/kg |
| Administration: | S.c. |
| Result: | A complete blockade of the nicotine effect produced by the training dose of nicotine (0.2 mg/kg). |
安全信息
| 安全说明 | 22-36 |
|---|---|
| WGK Germany | 3 |
| RTECS号 | KF3325000 |
| 提供商 | 语言 |
|---|---|
|
英文
|
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/04/30 | HY-107670 | (2S,13BS)-2-METHOXY-2,3,5,6,8,9,10,13-OCTAHYDRO-1H,12H-BENZO[I]PYRANO[3,4-G]INDOLIZIN-12-ONE HYDROBROMIDE Dihydro-β-erythroidine hydrobromide | 29734-68-7 | 5mg | 4050元 |
| 2024/04/30 | HY-107670 | (2S,13BS)-2-METHOXY-2,3,5,6,8,9,10,13-OCTAHYDRO-1H,12H-BENZO[I]PYRANO[3,4-G]INDOLIZIN-12-ONE HYDROBROMIDE Dihydro-β-erythroidine hydrobromide | 29734-68-7 | 10mg | 6900元 |